title: Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility.
abstract: The role of gastrointestinal motility and pH in determining cimetidine bioavailability as well as double peaks in plasma profiles following oral administration, in the quiescent or active phase of antral motility, to humans in the fasted state was examined. Plasma cimetidine-time curves did not show the presence of double peaks in any subject following intravenous administration. The incidence of double peaks was 73% following oral administration and was independent of antral migrating motility complex phase. Further, it was found that oral administration of cimetidine in the quiescent phase resulted in significantly higher bioavailability and in other pharmacokinetic parameters compared to that obtained following administration in the active phase. Excellent linearity in plots of motility peaks vs. plasma peaks with slopes close to unity were evident for both quiescent (r(2)=0.93) and active phase (r(2)=0.97) administration. A total of 14 peaks out of 22 (10 subjects, 64%) and 20 out of 27 peaks (11 subjects, 74%), were accounted for in quiescent and active phase oral administration, respectively. The proximal occurrence of plasma peaks to antral motility peaks typical of phase III contractions strongly implies that motility patterns may be responsible for secondary maxima following oral cimetidine administration in the fasted state.
authors.affiliation: Yamanouchi Pharmaceutical Co. Ltd., Shizuoka, Japan.
authors.forename: Narushi
authors.initials: N
authors.lastname: Takamatsu
authors.forename: Lynda S
authors.initials: LS
authors.lastname: Welage
authors.forename: Yayoi
authors.initials: Y
authors.lastname: Hayashi
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Yamamoto
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Barnett
authors.forename: Vinod P
authors.initials: VP
authors.lastname: Shah
authors.forename: Lawrence J
authors.initials: LJ
authors.lastname: Lesko
authors.forename: Chandrasekharan
authors.initials: C
authors.lastname: Ramachandran
authors.forename: Gordon L
authors.initials: GL
authors.lastname: Amidon
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000897:Anti-Ulcer Agents / Q000097:blood / Q000493:pharmacokinetics; D019540:Area Under Curve; D002927:Cimetidine / Q000097:blood* / Q000493:pharmacokinetics*; D005215:Fasting / Q000378:metabolism*; D005260:Female; D005769:Gastrointestinal Motility / Q000502:physiology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007408:Intestinal Absorption / Q000502:physiology*; D008297:Male; D011706:Pyloric Antrum / Q000502:physiology*
chemical_list: D000897:Anti-Ulcer Agents; D002927:Cimetidine